Tikkakoski T, Mäkelä J T, Leinonen S, Päivänsalo M, Merikanto J, Karttunen A, Siniluoto T, Kairaluoma M I
Department of Diagnostic Radiology, Oulu University Hospital, Finland.
J Vasc Interv Radiol. 1996 Mar-Apr;7(2):235-9. doi: 10.1016/s1051-0443(96)70767-4.
To evaluate the safety and efficacy of percutaneous aspiration and ethanol sclerotherapy as the sole treatment for symptomatic, nonneoplastic, congenital hepatic cysts.
In a prospective study, 59 symptomatic, congenital hepatic cysts in 25 patients were treated with ultrasound-guided percutaneous aspiration and ethanol sclerotherapy. Eleven patients had a solitary cyst, and 14 patients had polycystic liver disease. Mean follow-up was 4 years.
Fifty-seven (97%) of 59 sclerotherapy procedures were technically successful, and there were no recurrences. Eight cysts in six patients disappeared totally. The mean diameter of the remaining 49 cysts decreased from 9 cm to 3 cm. At the last follow-up visit, 14 patients were asymptomatic, four had milder epigastric pain than before the treatment, and seven with polycystic liver disease had recurrent symptoms due to growth of nontreated cysts. No major complications occurred.
Percutaneous aspiration with ethanol sclerotherapy is a safe, effective, and minimally invasive treatment method for symptomatic congenital cysts. It is the initial treatment of choice for all patients with symptomatic congenital hepatic cysts.
评估经皮穿刺抽吸及乙醇硬化疗法作为有症状的非肿瘤性先天性肝囊肿唯一治疗方法的安全性和有效性。
在一项前瞻性研究中,对25例患者的59个有症状的先天性肝囊肿采用超声引导下经皮穿刺抽吸及乙醇硬化疗法进行治疗。11例患者有单个囊肿,14例患者有多囊肝疾病。平均随访时间为4年。
59次硬化治疗中有57次(97%)在技术上成功,且无复发。6例患者的8个囊肿完全消失。其余49个囊肿的平均直径从9厘米降至3厘米。在最后一次随访时,14例患者无症状,4例患者上腹部疼痛较治疗前减轻,7例多囊肝疾病患者因未治疗囊肿的生长而出现复发症状。未发生重大并发症。
经皮穿刺抽吸联合乙醇硬化疗法是治疗有症状先天性囊肿的一种安全、有效且微创的治疗方法。它是所有有症状先天性肝囊肿患者的首选初始治疗方法。